Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Alzheimer's disease market: hope deferred

Nature Reviews Drug Discovery volume 12, pages 19–20 (2013)Cite this article

Subjects

The complex aetiology of AD is not fully resolved, although toxic isoforms of soluble intracellular and oligomeric or extracellular amyloid-β (Aβ) plaques as well as phosphorylated tau proteins are strongly implicated in mitochondrial dysfunction, synaptotoxicity, inflammation and neuronal loss. Diagnosis is largely dependent on cognitive and functional assessments. However, the accumulation of Aβ occurs 10–15 years before clinical symptoms manifest.

Treatment for Alzheimer's disease

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The mode of action categories of developmental drugs across clinical Phase I, II and III trials.
Figure 2: Aggregate sales forecast by active pharmaceutical ingredient in the top seven developed markets.

References

  1. Wischik, C. M. et al. O3-04-07: Tau aggregation inhibitor (TAI) therapy with Rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. Alzheimers Dement. 4, T167 (2008).

    Article  Google Scholar 

  2. Mullard,A. Sting of Alzheimer's failures offset by upcoming prevention trials. Nature Rev. Drug Discov. 11, 657–660 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Zelicia Gerald and Waldemar Ockert are at GBI Research, Knowsley House, Knowsley Street, Bolton BL1 2AH, UK.,

    Zelicia Gerald & Waldemar Ockert

Authors
  1. Zelicia Gerald
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Waldemar Ockert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Waldemar Ockert.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links

Related links

FURTHER INFORMATION

Author's homepage

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gerald, Z., Ockert, W. Alzheimer's disease market: hope deferred. Nat Rev Drug Discov 12, 19–20 (2013). https://doi.org/10.1038/nrd3922

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3922

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research